Showing results (221-230 of 248) with videos related to
Sort By:
Pageof 25
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 26, 2018
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group StudyMichael R McClung, Jacques P Brown, Adolfo Diez-Perez, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 7, 2009
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone massD L Kendler, L Bessette, C D Hill, et al.Calcified Tissue International|April 2, 2008
Sequestosome 1 (SQSTM1) mutations in Paget's disease of bone from the United StatesEmily C Rhodes, Teresa L Johnson-Pais, Frederick R Singer, et al.Obstetrics and Gynecology|July 2, 2013
Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trialChris Recknor, Edward Czerwinski, Henry G Bone, et al.The Journal of Clinical Endocrinology and Metabolism|June 9, 2016
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral BisphosphonatesP D Miller, N Pannacciulli, J P Brown, et al.The Journal of Clinical Endocrinology and Metabolism|May 26, 2018
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal OsteoporosisHenry G Bone, Felicia Cosman, Paul D Miller, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 30, 2014
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture TrialH G Bone, D W Dempster, J A Eisman, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 5, 2002
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosisR Rizzoli, S L Greenspan, G Bone, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 27, 2010
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effectJohn A Eisman, Henry G Bone, David J Hosking, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 7, 2011
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosisMichael R McClung, Steven Boonen, Ove Törring, et al.Pageof 25